| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453163 | Journal of Bone Oncology | 2018 | 5 Pages |
Abstract
History of alendronate use is associated with a lower likelihood of bone metastases in postmenopausal women with early breast cancer. Oral bisphosphonate treatment could be sufficient for reducing the risk of bone metastases.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Vanessa Rouach, Inbal Goldshtein, Ido Wolf, Raphael Catane, Gabriel Chodick, Amit Iton, Naftali Stern, Daniel Cohen,